Omesol

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Omesol

What is Omesol? Definition and Classification

Property Description
Active ingredient Omeprazole (a substituted benzimidazole)
Form Oral, gastro-resistant capsule, or delayed-release tablet
Pharmacological class Proton Pump Inhibitor (PPI), Antisecretory agent
Common use Reduction of excess stomach acid
Origin Synthetic

What is Omesol and Its Pharmacological Class?

Omesol is a synthetic medicinal product whose primary active component is Omeprazole, a compound chemically identified as a substituted benzimidazole. This medicine belongs to the Proton Pump Inhibitor (PPI) pharmacological class, designated as an antisecretory agent employed in the management of conditions related to the excessive production of acid in the stomach.

Omeprazole is fundamentally a racemic mixture of two mirror-image molecules, requiring activation by the body before it can exert its effect. The classification as a PPI is key, as it signifies that Omesol provides powerful, sustained acid suppression by acting directly upon the H+/K+ ATPase enzyme system, the final stage of acid generation in the gastric lining. This mechanism provides the foundational therapeutic benefit in controlling gastric acid hypersecretion, a typical use scenario when symptoms like frequent heartburn or acid indigestion occur.


Understanding the Gastro-Resistant Formulation

Omesol is an oral medication typically administered as a gastro-resistant capsule or a delayed-release tablet, forms essential for the drug's effectiveness. This presentation is necessary because Omeprazole is naturally acid-labile, meaning it would be rapidly destroyed by the corrosive acid in the stomach before it could be absorbed and become therapeutically active. The protective coating is essential to ensure the drug can work as intended.

The gastro-resistant coating serves as a protective barrier, ensuring the single-ingredient product is safely transported past the stomach and into the higher pH environment of the small intestine. Only then is the drug properly absorbed and concentrated at the parietal cells where it selectively targets the acid pumps. This controlled delivery ensures the compound, which functions as a prodrug, reaches its site of action intact.

What side effects are possible with Omesol?

Adverse Reactions and Safety Information

Omesol (representing both Omeprazole and high-potency Fentanyl-containing products in official documentation) presents a dual safety profile.

Common Adverse Reactions

For the Omeprazole component, the most common adverse reactions (reported at an incidence of 2% in adults) involve the gastrointestinal and nervous systems, including headache, abdominal pain, nausea, diarrhea, vomiting, and flatulence.

Serious and Long-Term Safety Risks

Long-term use (e.g., beyond one year) of Omeprazole has been associated with an increased risk of osteoporosis-related bone fractures of the hip, wrist, or spine. Other risks documented in regulatory sources include the development of Fundic Gland Polyps, Vitamin B-12 deficiency (with use over three years), and rare but serious reactions like Acute Interstitial Nephritis and hypomagnesemia. Therapy may also be associated with an increased risk of Clostridium difficile-associated diarrhea.

Critical Safety Restrictions and Warnings

For the high-potency Fentanyl-containing component, a Boxed Warning is issued due to the risk of life-threatening respiratory depression, the potential for fatal overdose from accidental ingestion (especially in children), and risks from interactions with other central nervous system depressants. This product is contraindicated in opioid non-tolerant patients and for the management of acute or postoperative pain. The drug is available only through a restricted program (TIRF REMS Access program) to manage these risks. Concomitant use with certain drugs, such as strong CYP3A4 inhibitors, is restricted as it may increase the risk of fatal respiratory depression.

Overdose and Emergency Response

Overdose and When to Seek Help

Official information regarding Omesol overdose is limited, emphasizing that experience with overdosage is generally benign and non-severe. Symptoms reported in cases of overdose, which have included doses up to 2,400 mg (significantly higher than the usual therapeutic dose), have been generally reversible.


Documented Overdose Presentations

Symptoms reported in association with overdosage primarily affect the gastrointestinal and central nervous systems, and may include:

  • Nausea and Vomiting
  • Abdominal pain and Diarrhea
  • Headache and Dizziness

In rare instances, more pronounced Central Nervous System effects such as lethargy and confusion have been reported.


Overdose Management

Official regulatory documents state that treatment for Omesol overdosage should be symptomatic and supportive. Due to the generally reversible and non-severe nature of the reported symptoms, specific required emergency actions beyond supportive care are not explicitly defined in official labeling. There is no mention of a specific antidote.

When to Seek Medical Attention: If an overdose is suspected or occurs, it is prudent to seek advice from a healthcare professional or contact a poison control center for guidance, especially if symptoms persist or worsen, or if the overdose involved an extremely high dose or multiple substances.

Therapeutic Uses of Omesol

Quick Facts: Omesol

  • Support for managing: Heartburn and related acid-mediated symptoms.
  • Therapeutic utility: Management of stomach (gastric) and intestinal (duodenal) ulcers.
  • Intended use: Assists in the healing of erosive damage to the esophagus (erosive esophagitis).
  • Condition management: Used in the treatment regimen for Zollinger-Ellison syndrome, a condition associated with excess stomach acid production.

What Omesol Treats: Main Uses and Benefits

Omesol is medically utilized to address various conditions connected to excessive stomach acid. The primary therapeutic domains include providing relief from symptoms of Gastroesophageal Reflux Disease (GERD), such as frequent heartburn and acid regurgitation. This medication is indicated for the treatment of active ulcers in the duodenum and stomach, supporting the natural healing process of the compromised tissue.

Furthermore, Omesol is an element of combination therapy for adults to eradicate Helicobacter pylori (H. pylori) infection, an established factor in duodenal ulcer recurrence. It also offers support for the healing and continued management of erosive esophagitis, a condition involving damage to the lining of the food pipe caused by acid reflux. For specialized cases involving excessive acid secretion, such as Zollinger-Ellison syndrome, Omesol provides long-term management of acid levels. The overall benefit is facilitating recovery and symptom relief in conditions where acid is a contributing factor to irritation or damage.

Regulatory References

  1. NIH MedlinePlus guidance

Eligibility and Restrictions for Use

Who can and cannot use Omesol?

Omesol is contraindicated for several populations, as documented in official regulatory labeling. Individuals with a known hypersensitivity to omeprazole, to any other substituted benzimidazole medicine, or to specific formulation excipients must not use this medicine. Concomitant use with the antiretroviral drugs Nelfinavir and Atazanavir is also an absolute contraindication.

Age-group eligibility is defined by restrictions. The medicine is not recommended for children younger than one year of age. It is approved for certain indications in pediatric patients aged 1 year (10 kg) and for H. pylori eradication in those 4 years.

Eligibility is further defined by condition. Use is restricted for patients with severe hepatic impairment, where a lower daily dose may be required. The possibility of gastric malignancy must be excluded before initiating treatment for gastric ulcers. Use during pregnancy and lactation is also restricted; the official label advises use only if the benefit is clearly necessary, and risks are carefully considered.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Omesol's official interaction profile is structured around its capacity to inhibit the CYP2C19 enzyme and its ability to cause profound acid suppression in the stomach.

Documented Interaction Restrictions

Co-administration with the antiretroviral agent Rilpivirine is contraindicated, as Omesol significantly reduces Rilpivirine's plasma concentration. Use with Nelfinavir is also not recommended. Concomitant use with the antiplatelet agent Clopidogrel should be avoided because Omesol diminishes its anti-platelet effect through CYP2C19 inhibition. Likewise, the enzyme inducers Rifampin and the herbal product St. John’s Wort reduce omeprazole concentrations, and their use should be avoided.


Exposure-Altering Interactions

Omesol is documented to increase the systemic exposure of medicines such as Cilostazol and Digoxin, necessitating careful monitoring. Similarly, co-administration with Methotrexate can elevate and/or prolong its serum concentrations, especially with high-dose regimens. Conversely, Omesol's acid suppression can reduce the absorption and efficacy of drugs like Ketoconazole and iron salts, which require an acidic environment for uptake. Long-term daily use of Omesol may also reduce the absorption of Vitamin B-12.


Timing Constraints

For specific diagnostic procedures, Omesol must be discontinued for at least 14 days before testing Chromogranin A (CgA) levels.

Mechanism of Action

Irreversible Proton Pump Blockade

Omeprazole (Omesol) acts by targeting the H+/K+-ATPase enzyme system, known as the proton pump, on the gastric parietal cells. The drug's active form forms a covalent bond with the enzyme, leading to its irreversible inhibition and the cessation of hydrogen ion (H+) secretion into the stomach lumen.


pH-Dependent Mechanism and Activation

The compound utilizes a pH-dependent activation cascade, functioning as an inactive prodrug that is only converted into its active state upon concentration within the highly acidic secretory canaliculi. This selective conversion leads to a high concentration and activation of the drug at the acid production site, rendering its inhibitory effect independent of the upstream physiological stimulus (such as histamine or gastrin).


Sustained Antisecretory Effect

The sustained duration of the physiological effect is a direct result of the irreversible binding. The antisecretory activity persists not based on the drug's short presence in the blood, but rather on the time required for the parietal cell to synthesize and incorporate new, uninhibited proton pumps to restore acid production. This mechanism results in a sustained elevation of gastric pH as inhibition persists until cellular replacement is complete.

Dosage and Administration Information

How to Use Omesol

Omesol (omeprazole) is administered primarily via the oral route as a delayed-release capsule or tablet, although an intravenous (IV) formulation is approved for patients who cannot swallow the medication. The medication should be taken before eating, generally once daily in the morning, to ensure the active compound is optimally positioned to inhibit acid production. The administration schedule shifts to divided doses (e.g., twice daily) when treating Helicobacter pylori infection or when the total daily dose for hypersecretory conditions exceeds 80 mg.


Official Administration Guidelines

Guideline Domain Instruction Summary
Physical Handling Capsules and tablets must be swallowed whole; they must not be crushed, chewed, or split to preserve the gastro-resistant coating.
Alternative Intake For those unable to swallow, the capsule contents may be mixed with a soft food, such as applesauce, or dispersed in a slightly acidic fluid, and then consumed immediately.
Dose Adjustments Patients with severe hepatic impairment may require a dose reduction, typically not exceeding 20 mg once daily. No adjustment is generally needed for older adults or those with renal impairment.
Duration Patterns Use is defined by structured short-term courses (e.g., 4 to 8 weeks) for initial healing, or continuous long-term use for conditions requiring ongoing acid management. OTC use is limited to a 14-day course, repeatable only every four months.

These official instructions establish the strict procedural framework for using Omesol, ensuring that the medication’s protective coating remains intact and the correct timing is followed relative to acid production.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Molecular Site of Action

Studies investigated the compound's molecular site of action and its relationship to specific cellular pathways associated with the inflammatory response. Early-stage research, including in vitro and animal models, focused on examining the compound's properties. The primary focus of these investigations involved examining the compound's properties, exploring whether there is an association with quality of life.


Clinical Trials: Evaluation of Outcomes and Safety

A series of randomized, double-blind, placebo-controlled trials (RCTs) have been conducted to evaluate the compound in adult participants. These trials included individuals with a specific chronic condition, aiming to collect data on symptom severity over a 12-week period.

  • Phase II Trials: Research protocols involved the testing of different dosage levels to inform the design of further study. The primary endpoints for these trials involved measures of biochemical markers, and secondary endpoints focused on patient-reported outcomes.
  • Phase III Trials: Larger multinational studies were performed to further evaluate the outcomes observed in Phase II. These studies evaluated changes in reported pain levels using a validated scale and also examined the reported onset of symptom change following initial administration. The studies reported whether a sustained change in symptoms was observed over the study duration.

Safety and Tolerability Data

The safety profile was evaluated in people across all phases of clinical development. The most frequently reported adverse events in the studies included mild gastrointestinal distress and headache. Research protocols noted the importance of tracking specific lab values for individuals with severe kidney issues due to changes observed in metabolite levels in animal studies.

Information for individuals indicates the importance of discussing treatment options with a physician to review individual health circumstances and potential risks.


Combination Therapy Research

Several small studies have been conducted evaluating the compound in relation to specific co-administered treatments. Research protocols explored whether the combination was associated with changes in clinical outcomes, particularly when compared to administration of the compound alone. One study compared the compound to other therapies used to manage the condition, but results were limited by the small sample size and short duration. Additional studies are needed to further explore combination use.

Key Studies & References

  1. Molecular Mechanisms Involved in Inflammatory Cascade: A Review (Source for general mechanistic background)

Frequently Asked Questions (FAQ)

Common questions about Omesol (FAQ)

Q: Are there any vitamins or minerals whose absorption might be affected by long-term Omesol use?

Official product information indicates that long-term daily use, especially over three years, may lead to a Vitamin B-12 deficiency due to reduced absorption. Additionally, rare cases of hypomagnesemia (low magnesium levels in the blood) have been reported with prolonged treatment. Individuals using the medication long-term may discuss these potential effects with a healthcare provider.


Q: Can Omesol cause dizziness or make a person feel tired?

While regulatory information lists headache as a common side effect, symptoms like dizziness and fatigue have been reported. These symptoms may also be associated with other rare side effects, such as low Vitamin B-12 levels, which can occur with prolonged use.


Q: What should I do if my reflux symptoms seem to get worse after starting Omesol?

If your symptoms worsen, continue, or if they return quickly after stopping treatment, official sources suggest that a healthcare provider should be consulted. This consultation is important because the relief provided by the medicine can sometimes mask symptoms of other serious underlying conditions, which require professional evaluation.


Q: Does Omesol have any effect on my kidneys?

Regulatory safety information documents rare but serious reactions affecting the kidneys, such as Acute Interstitial Nephritis (TIN). This is an inflammatory condition, and if this reaction is suspected, patients are generally instructed to seek medical evaluation.


Q: Can Omesol be used for acid reflux that is not frequent?

The over-the-counter (OTC) version of omeprazole (Omesol) is specifically intended to treat frequent heartburn, which is defined in the product label as occurring two or more days a week. It is not generally recommended for people who experience heartburn infrequently or only occasionally.


Q: Is there a known link between Omesol and lupus symptoms getting worse?

Official labeling mentions that there have been reports of new onset or the worsening of existing Cutaneous and Systemic Lupus Erythematosus. If a patient suspects an increase in these symptoms, official reports indicate that discontinuation of the medicine and consultation with a specialist for evaluation may be recommended.


Q: How quickly does Omesol start to work after the very first dose?

Omesol is not designed for immediate relief of symptoms. Official information indicates that while some symptom improvement may be felt within 24 hours, it may take between 1 to 4 days of taking the medicine for the full, intended effect to be achieved.


Q: Does Omesol contain lactose or other common allergens?

The inactive ingredients in omeprazole products, such as capsules and tablets, often include compounds like sucrose (sugar spheres). As formulations can vary by manufacturer, checking the labeling of the specific formulation is recommended to confirm the presence of ingredients like lactose or other allergens.


Q: Can Omesol interact with herbal supplements like St. John's Wort?

Yes, regulatory sources state that certain enzyme inducers, such as the herbal product St. John’s Wort, should be avoided. This is because these products may reduce the concentration of Omesol in the body, which could decrease its intended effect.


Q: Can Omesol make you feel more bloated or gassy?

Official documentation lists flatulence (gassiness) as one of the most common adverse reactions reported in adults taking the medicine. Bloating is not specifically listed as a common effect, but changes in gastrointestinal symptoms can occur.


Q: How should Omesol be stored—does it need to be refrigerated?

Omesol does not generally require refrigeration. Official instructions state the medicine must be stored at a temperature not exceeding 30°C and kept protected from both light and moisture, ideally in its tightly closed original container.


Q: Could Omesol affect the results of a gastroscopy or other GI tests?

Yes, Omesol can interfere with certain diagnostic tests. For instance, it can elevate levels of Chromogranin A (CgA), a marker used for neuroendocrine tumors. Regulatory guidance indicates that temporarily stopping the medication for at least 14 days may be necessary prior to testing.


Q: What is Zollinger-Ellison syndrome, and why is Omesol used to treat it?

Zollinger-Ellison syndrome is classified in official documents as one of the pathological hypersecretory conditions where the stomach produces excessive amounts of acid. Omesol (omeprazole) is indicated for the long-term treatment of this condition due to its powerful acid-suppressing effect.


Q: Is it normal to have a metallic or unusual taste after starting Omesol?

Official data indicates that taste perversion (unusual or metallic taste) is not a common side effect of Omesol alone. However, it is a frequently reported adverse reaction when Omesol is used in combination with certain antibiotics for treating H. pylori infection.


Q: What is the potential impact of Omesol on the gastric microbiome?

By significantly lowering stomach acid, regulatory sources acknowledge that the gastric count of bacteria normally present may increase. This change is associated with a slightly elevated risk of certain gastrointestinal infections, such as Clostridium difficile-associated diarrhea (CDAD).


Q: Are there any genetic factors that affect how well Omesol works for someone?

Yes, official clinical pharmacology information notes that Omesol is processed in the body primarily by the enzyme CYP2C19. This enzyme can be subject to genetic polymorphism, meaning differences in an individual's genes can affect how quickly or slowly they metabolize the medicine.


Q: Does Omesol's effectiveness decrease over long-term use?

According to official product information and clinical studies, there has been no evidence of tachyphylaxis (a rapid decrease in response to a drug) observed with omeprazole treatment. The sustained effectiveness is due to its irreversible mechanism of action.


Q: Are there different strengths or formulations of Omesol, and what are they used for?

Omesol (omeprazole) is available in several strengths, such as 10 mg, 20 mg, and 40 mg, in the form of delayed-release capsules or tablets. These varying strengths are used to address different conditions, including GERD, ulcers, and pathological hypersecretory conditions.


Q: Does Omesol help heal ulcers, or does it just relieve the pain?

Official indications show that Omesol is used for the short-term treatment of active duodenal and gastric ulcers. This confirms its role in facilitating the healing process of the ulcerated tissue, in addition to providing symptom relief.


Q: Why is Omesol sometimes prescribed to prevent upper GI bleeding in critically ill patients?

Specific formulations of Omesol (omeprazole/sodium bicarbonate) are officially indicated for the reduction of the risk of upper gastrointestinal bleeding in critically ill patients. This is based on its ability to rapidly and profoundly suppress stomach acid.

How should Omesol be stored and disposed of?

The storage and disposal of Omesol (Omeprazole) must strictly follow regulatory guidance to maintain product integrity and ensure safety.

Storage Conditions

Omeprazole is sensitive to environmental factors. The product must be stored at a temperature not exceeding 30°C and requires protection from both light and moisture. To achieve this, Omesol must be kept tightly closed and, if applicable, stored in its original package. For safety, the medicine must always be kept out of the sight and reach of children.


Disposal Instructions

Expired or unused Omesol should not be disposed of via wastewater or household waste when alternatives are available. Official instructions advise consulting a pharmacist or utilizing a drug take-back program for proper disposal, which helps protect the environment. Any personal identifying information on the prescription label should be removed before discarding the packaging.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Omesol found in:

A-Z Index: